SCHEMBL10076069

SCHEMBL10076069

CCC(=O)N1CCN(CC(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
ALDH1A1 P00352 3/20 0.41
DRD3 P35462 1/20 0.40
GAA P10253 1/20 0.39
BLM P54132 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SIGMAR1 Q99720 2/20 0.36
TERT O14746 1/20 0.36
HSD11B1 P28845 2/20 0.36
DTYMK P23919 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7132345 0.90 GAA (0.50) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL28507625 0.87 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL3799622 0.86 PLA2G10 (0.41) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL27147241 0.86 PLA2G10 (0.41) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL3470166 0.86 PLA2G10 (0.41) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL7132777 0.85 GAA (0.50) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL31505475 0.84 GAA (0.44) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL14080586 0.83 CHRM2 (0.42) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL28515122 0.83 PIK3CD (0.46) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL15315922 0.83 CHRM2 (0.55) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3186227-B1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS ELANCO TIERGESUNDHEIT AG (CH) 2021-03-24 EP disclosed
US-10464889-B2 Sulfonylaminobenzamide compounds as anthelmintics ELANCO TIERGESUNDHEIT AG (US) 2019-11-05 US disclosed
US-20170226053-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS NOVARTIS TIERGESUNDHEIT AG (CH) 2017-08-10 US disclosed
US-20170226053-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS NOVARTIS TIERGESUNDHEIT AG (CH) 2017-08-10 US disclosed
WO-2016033341-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS NOVARTIS TIERGESUNDHEIT AG (CH) 2016-03-03 WO disclosed
EP-2990403-A1 ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS Novartis Tiergesundheit AG (CH) 2016-03-02 EP disclosed
US-8093231-B2 Sulfonylethyl phosphorodiamidates TELIK, INC. (US) 2012-01-10 US disclosed
US-20080039429-A1 SULFONYLETHYL PHOSPHORODIAMIDATES TELIK, INC. 2008-02-14 US disclosed
US-7262182-B2 Sulfonylethyl phosphorodiamidates TELIK, INC. (US) 2007-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226053-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS PKD2, CATSPER1, PKD1 CHRM2 3471/4885CHRM4 3824/4885CHRM1 3750/4885
US-20080039429-A1 SULFONYLETHYL PHOSPHORODIAMIDATES MTAP, TYMP, PHOSPHO1 CHRM2 4786/4885CHRM4 4721/4885CHRM1 4865/4885
US-10464889-B2 Sulfonylaminobenzamide compounds as anthelmintics PKD2, CATSPER1, ATP1B2 CHRM2 3452/4885CHRM4 3980/4885CHRM1 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.